Sarah Owermohle

States’ vaccine prizes fizzle — With Obamacare safe, new battles begin

Former FDA chief joins venture capital group — ACA enrollment slows

Lab leak theory attracts global interest — After approval of new Alzheimer’s drug, crickets from Congress

Latest news and analysis on coronavirus.

Janet Woodcock did not release a statement with the approval — noteworthy considering it was the first new Alzheimer’s drug in nearly two decades.

And Senate Democrats threaten subpoenas over DOJ’s reported secret lawmaker subpoenas.

President Joe Biden will announce the plan tomorrow ahead of the G-7 meeting in the United Kingdom.

FDA ignites debate with approval of Alzheimer’s drug — HHS and Texas tussle over facilities for migrant children

Federal and state consent laws factor in whether at-risk youths will gain access to the shots.

And Texas prepares to pass a major voting restrictions bill.

Researchers say the lack of enough drugs for mildly ill patients means that the world may never completely stamp out the virus.

Restarting Emergent’s production of the J&J shot would revitalize efforts to get the single-dose vaccine to many Americans.

Biden drawn into abortion fight — House members set to grill AbbVie on drug prices

What the border emergency is costing HHS — Covid-19 long-haulers push for a patient registry

Biden’s CMS pick faces key vote — No J&J doses for states this week

The CDC panel voted 14-0 with one recusal on Wednesday in favor of expanding use of the shot, days after the FDA authorized its use in the same age group.

Where docs go to talk to teens about vaccines  Politico

Assistant health secretary vote today — Lining up docs to give Covid shots

The prospect of abandoning vaccine patents to allow broad global production has pitted public health advocates against industry.

The results from a preliminary study are an early sign that booster shots could play a role in future vaccination efforts.